3-(1-azepanylsulfonyl)-n-(3-bromphenyl)benzamide profile

3-(1-azepanylsulfonyl)-N-(3-bromphenyl)benzamide: a sirtuin 2 inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	1328033
CHEMBL ID	3222141
SCHEMBL ID	1095726
MeSH ID	M000613287

Synonym
EU-0004902
ak-7
OPREA1_876929
3-(azepan-1-ylsulfonyl)-n-(3-bromophenyl)benzamide
chembl3222141 ,
bdbm50008859
AKOS001632674
420831-40-9
NCGC00347936-01
S5914
CS-3223
HY-16691
MLS006011706
smr004703433
3-(azepane-1-sulfonyl)-n-(3-bromophenyl)benzamide
benzamide, n-(3-bromophenyl)-3-((hexahydro-1h-azepin-1-yl)sulfonyl)-
308b6b695n ,
unii-308b6b695n
AB00115363-01
SCHEMBL1095726
n-(3-bromophenyl)-3-[(hexahydro-1h-azepin-1-yl)sulfonyl]benzamide
ak 7
AC-35414
HB3747
c19h21brn2o3s
3-(1-azepanylsulfonyl)-n-(3-bromophenyl)benzamide
DTXSID30194926
SR-01000432494-1
sr-01000432494
ak-7, >=98% (hplc)
NCGC00347936-06
sirt2 inhibitor ii, ak-7
FT-0702786
Z27789153
BS-16806
BCP09325
EN300-122270
HMS3886F07
HMS3740I05
Q27255930
3-(1-azepanylsulfonyl-)-n-(3-bromophenyl)benzamide
EX-A4162
VRA83140
3-(1-azepanylsulfonyl)-n-(3-bromphenyl)benzamide

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" These candidates were subjected to a dose-response bioactivity assay, measuring an increase in α-tubulin K40 acetylation in two neuronal cell lines, which yielded five compounds bioactive in both cell lines and eight compounds bioactive in at least one of the cell lines tested."	( Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors. Choi, SH; Kazantsev, AG; Khanfar, MA; Quinti, L; Silverman, RB; Wang, H, 2014)	0.4

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Fumarate hydratase	Homo sapiens (human)	Potency	37.2212	0.0030	8.7949	48.0869	AID1347053
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	3.3786	0.0123	7.9835	43.2770	AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	24.2014	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
G	Vesicular stomatitis virus	Potency	6.0081	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	8.4866	0.0010	8.3798	61.1304	AID1645840
polyprotein	Zika virus	Potency	37.2212	0.0030	8.7949	48.0869	AID1347053
Interferon beta	Homo sapiens (human)	Potency	6.0081	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	6.0081	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	6.0081	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	6.0081	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)	IC50 (µMol)	2,595.8333	0.5000	3.8481	10.0000	AID1119559; AID1129418; AID1176357; AID1229524; AID1585823; AID1652961
NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)	IC50 (µMol)	50.0000	0.0060	1.6250	9.0000	AID1176362
NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)	IC50 (µMol)	50.0000	0.8500	5.4300	10.0000	AID1176364
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
rDNA heterochromatin formation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
protein deacetylation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
autophagy	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
mitotic nuclear membrane reassembly	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
regulation of exit from mitosis	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of autophagy	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of peptidyl-threonine phosphorylation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
substantia nigra development	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
myelination in peripheral nervous system	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
heterochromatin formation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
subtelomeric heterochromatin formation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
regulation of myelination	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
cellular response to oxidative stress	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
peptidyl-lysine deacetylation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
epigenetic regulation of gene expression	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of protein catabolic process	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
regulation of phosphorylation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of DNA binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
post-translational protein modification	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
cellular lipid catabolic process	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NLRP3 inflammasome complex assembly	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
innate immune response	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of fat cell differentiation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of fatty acid biosynthetic process	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of meiotic nuclear division	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of striated muscle tissue development	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of DNA-templated transcription	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
cell division	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
meiotic cell cycle	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
regulation of cell cycle	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
response to redox state	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of cell division	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of attachment of spindle microtubules to kinetochore	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
cellular response to caloric restriction	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of oligodendrocyte progenitor proliferation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
cellular response to hypoxia	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
cellular response to epinephrine stimulus	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
tubulin deacetylation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of execution phase of apoptosis	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
positive regulation of oocyte maturation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of NLRP3 inflammasome complex assembly	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of satellite cell differentiation	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
single strand break repair	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
rDNA heterochromatin formation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
pyrimidine dimer repair by nucleotide-excision repair	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
DNA synthesis involved in DNA repair	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
angiogenesis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
ovulation from ovarian follicle	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
intracellular glucose homeostasis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of protein phosphorylation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of endothelial cell proliferation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of adaptive immune response	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
chromatin organization	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
DNA methylation-dependent heterochromatin formation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
protein deacetylation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
triglyceride mobilization	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
DNA damage response	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
response to oxidative stress	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
spermatogenesis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of mitotic cell cycle	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
muscle organ development	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of cell population proliferation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cellular response to starvation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of gene expression	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of centrosome duplication	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of triglyceride biosynthetic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of cholesterol efflux	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of lipid storage	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of glucose metabolic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of macroautophagy	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
protein ubiquitination	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
peptidyl-lysine acetylation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
macrophage differentiation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of prostaglandin biosynthetic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
heterochromatin formation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
protein destabilization	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of TOR signaling	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of endodeoxyribonuclease activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
response to insulin	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
circadian regulation of gene expression	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
leptin-mediated signaling pathway	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of smooth muscle cell apoptotic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
intracellular triglyceride homeostasis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of peroxisome proliferator activated receptor signaling pathway	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of cell population proliferation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cellular response to glucose starvation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of phosphorylation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
response to hydrogen peroxide	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
behavioral response to starvation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cholesterol homeostasis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of apoptotic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of apoptotic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of apoptotic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transduction	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediator	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of neuron apoptotic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
response to leptin	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of MHC class II biosynthetic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of fat cell differentiation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of gluconeogenesis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of DNA repair	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of angiogenesis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of cell cycle	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of DNA-templated transcription	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of transcription by glucose	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of insulin receptor signaling pathway	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
white fat cell differentiation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of helicase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of smooth muscle cell differentiation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
maintenance of nucleus location	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
fatty acid homeostasis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of androgen receptor signaling pathway	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of macrophage cytokine production	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cellular response to hydrogen peroxide	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of bile acid biosynthetic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
UV-damage excision repair	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cellular response to tumor necrosis factor	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cellular response to hypoxia	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cellular response to ionizing radiation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of protein serine/threonine kinase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of brown fat cell differentiation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
stress-induced premature senescence	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
energy homeostasis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
protein depropionylation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
DNA repair-dependent chromatin remodeling	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of cellular response to heat	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of signal transduction by p53 class mediator	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of protein acetylation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of adipose tissue development	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cellular response to leukemia inhibitory factor	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of macrophage apoptotic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of cAMP-dependent protein kinase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of cAMP-dependent protein kinase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of cellular response to testosterone stimulus	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of peptidyl-lysine acetylation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of cellular senescence	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of cellular senescence	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of double-strand break repair	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
chromatin remodeling	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
protein deacetylation	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
aerobic respiration	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
positive regulation of insulin secretion	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
peptidyl-lysine deacetylation	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascade	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
positive regulation of superoxide dismutase activity	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
positive regulation of catalase activity	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
positive regulation of ceramide biosynthetic process	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
NAD+ ADP-ribosyltransferase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
chromatin binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NAD+ ADP-ribosyltransferase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
histone deacetylase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
protein binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
zinc ion binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NAD-dependent histone deacetylase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
protein lysine deacetylase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NAD-dependent protein lysine deacetylase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
histone acetyltransferase binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
histone deacetylase binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
tubulin deacetylase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
ubiquitin binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NAD+ binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
DNA-binding transcription factor binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NAD-dependent protein demyristoylase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
NAD-dependent protein depalmitoylase activity	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
transcription factor binding	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
NAD+ ADP-ribosyltransferase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
p53 binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
transcription coactivator activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
transcription corepressor activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
histone deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
protein binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nuclear receptor binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
NAD-dependent histone deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
enzyme binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
NAD-dependent histone H3K14 deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
protein lysine deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
NAD-dependent protein lysine deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
histone binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
identical protein binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
HLH domain binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
bHLH transcription factor binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
metal ion binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
NAD-dependent histone H3K9 deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
mitogen-activated protein kinase binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
lysine-acetylated histone binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
protein-propionyllysine depropionylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
DNA-binding transcription factor binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
histone H4K12 deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
histone H3K deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
NAD-dependent histone decrotonylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
keratin filament binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
promoter-specific chromatin binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
NAD+ binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
NAD+ ADP-ribosyltransferase activity	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activity	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
protein binding	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
zinc ion binding	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
enzyme binding	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
NAD-dependent protein lysine deacetylase activity	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
sequence-specific DNA binding	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
NAD+ binding	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
NAD-dependent histone deacetylase activity	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
chromosome, telomeric region	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
nucleus	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
chromosome	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
nucleolus	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
cytoplasm	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
mitochondrion	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
centrosome	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
centriole	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
spindle	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
cytosol	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
microtubule	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
plasma membrane	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
growth cone	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
midbody	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
paranodal junction	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
paranode region of axon	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
perikaryon	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
myelin sheath	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
lateral loop	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
Schmidt-Lanterman incisure	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
juxtaparanode region of axon	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
perinuclear region of cytoplasm	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
mitotic spindle	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
meiotic spindle	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
glial cell projection	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
heterochromatin	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
chromatin silencing complex	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
nucleus	NAD-dependent protein deacetylase sirtuin-2	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleolus	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cytoplasm	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
ESC/E(Z) complex	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cytosol	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
fibrillar center	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nucleus	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nuclear envelope	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nuclear inner membrane	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nucleoplasm	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nucleolus	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cytoplasm	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
mitochondrion	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cytosol	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
PML body	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
eNoSc complex	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
chromatin	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
euchromatin	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
heterochromatin	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
chromatin silencing complex	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
rDNA heterochromatin	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nucleus	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nuclear inner membrane	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nucleoplasm	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nucleoplasm	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
mitochondrion	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
mitochondrial matrix	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
protein-containing complex	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
nucleus	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (69)

Assay ID	Title	Year	Journal	Article
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1176362	Inhibition of human SIRT1	2015	Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2	Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
AID1129418	Inhibition of SIRT-2 (unknown origin)	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors.
AID1176358	Inhibition of GST-tagged human recombinant SIRT2 (34 to 356 residues) expressed in Escherichia coli BL21 at 10 uM using Fluor de Lys-SIRT as substrate incubated for 60 mins prior to substrate addition measured after 45 mins by fluorimetric analysis	2015	Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2	Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
AID1119559	Inhibition of recombinant human full length SIRT2 using fluorescent ZMAL as substrate after 4 hrs by homogeneous fluorescent deacetylase assay	2012	MedChemComm, Mar-01, Issue:3	The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID1652961	Inhibition of sirtuin 2 (unknown origin)	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	An overview of Sirtuins as potential therapeutic target: Structure, function and modulators.
AID1176364	Inhibition of human SIRT3	2015	Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2	Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
AID1119572	Cell cycle arrest in human MCF7 cells assessed as accumulation at G2-M phase at 50 uM after 24 hrs by flow cytometry (Rvb = 22.6 %)	2012	MedChemComm, Mar-01, Issue:3	The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID1176357	Inhibition of human recombinant SIRT2	2015	Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2	Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
AID1119565	Inhibition of SIRT2 in human MCF7 cells assessed as increase in hyperacetylation of alpha-tubulin up to 50 uM after 24 hrs by Western blot analysis	2012	MedChemComm, Mar-01, Issue:3	The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID1119569	Cell cycle arrest in human MCF7 cells assessed as accumulation at sub-G1 phase at 50 uM after 24 hrs by flow cytometry (Rvb = 0.3 %)	2012	MedChemComm, Mar-01, Issue:3	The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID1585823	Inhibition of SIRT2 (unknown origin) using fluorogenic deacetylase substrate by fluorescence assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Pharmaceutical significance of azepane based motifs for drug discovery: A critical review.
AID1119570	Cell cycle arrest in human MCF7 cells assessed as accumulation at G1 phase at 50 uM after 24 hrs by flow cytometry (Rvb = 43.5 %)	2012	MedChemComm, Mar-01, Issue:3	The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID1119562	Inhibition of recombinant human N-tagged GST-SIRT1 fusion protein using fluorescent ZMAL as substrate at 50 uM after 4 hrs by homogeneous fluorescent deacetylase assay	2012	MedChemComm, Mar-01, Issue:3	The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID1119567	Inhibition of SIRT1 in human MCF7 cells assessed as increase in acetylation of p53 at lys 382 at 50 uM after 24 hrs by Western blot analysis	2012	MedChemComm, Mar-01, Issue:3	The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID1119564	Inhibition of SIRT1 in human MCF7 cells assessed as increase in acetylation of H3-K9 up to 50 uM after 24 hrs by Western blot analysis	2012	MedChemComm, Mar-01, Issue:3	The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
AID1229524	Inhibition of SIRT2 (unknown origin)	2015	ACS medicinal chemistry letters, May-14, Volume: 6, Issue:5	Design and Evaluation of 3-(Benzylthio)benzamide Derivatives as Potent and Selective SIRT2 Inhibitors.
AID1119571	Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 50 uM after 24 hrs by flow cytometry (Rvb = 30.8 %)	2012	MedChemComm, Mar-01, Issue:3	The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	16 (64.00)	24.3611
2020's	9 (36.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (8.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	23 (92.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2.11	1	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.	2.52	2	methylpyridines; phenylpyridine; tetrahydropyridine	neurotoxin
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.1	1	aromatic ether; nitrile; polyether; tertiary amino compound
propantheline Propantheline: A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.	2.1	1	xanthenes
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.1	1	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
ranitidine [no description available]	2.1	1	aralkylamine
sevoflurane Sevoflurane: A non-explosive inhalation anesthetic used in the induction and maintenance of general anesthesia. It does not cause respiratory irritation and may also prevent PLATELET AGGREGATION.. sevoflurane : An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups.	2.25	1	ether; organofluorine compound	central nervous system depressant; inhalation anaesthetic; platelet aggregation inhibitor
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	2.1	1	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.	2.11	1	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
suramin sodium suramin sodium : An organic sodium salt that is the hexasodium salt of suramin. It is an FDA approved drug for African sleeping sickness and river blindness.	2.11	1	organic sodium salt	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
dibenzylamine 10,11-dihydro-5H-dibenzo(b,f)azepine: core structure of clomipramine	2.07	1
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.13	1	dialdehyde	biomarker
10,11-dihydrocarbamazepine [no description available]	2.07	1
ribavirin Rebetron: Rebetron is tradename	2.17	1	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
acamprosate Acamprosate: Structural analog of taurine that is used for the prevention of relapse in individuals with ALCOHOLISM.. acamprosate : An organosulfonic acid that is propane-1-sulfonic acid substituted by an acetylamino group at position 3.	2.17	1	acetamides; organosulfonic acid	environmental contaminant; neurotransmitter agent; xenobiotic
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	3.31	1	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
CAY10591 CAY10591: a SIRT1 NAD-dependent histone deacetylase activator	3.31	1	quinoxaline derivative
tamoxifen [no description available]	2.1	1	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
2,4-diaziran-1-yl-6-(1-phenyl-1H-pyrrol-2-yl)-1,3,5-triazine [no description available]	3.31	1	pyrroles
sirtinol [no description available]	2.07	1	aldimine; benzamides; naphthols	anti-inflammatory agent; EC 3.5.1.98 (histone deacetylase) inhibitor; Sir2 inhibitor
(4-chlorophenyl)-[4-(8-nitro-5-quinolinyl)-1-piperazinyl]methanone [no description available]	3.31	1	N-arylpiperazine
ex 527 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide: structure in first source. 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide : A member of the class of carbazoles that is 2,3,4,9-tetrahydro-1H-carbazole which is substituted at position 1 by an aminocarbohyl group and at position 6 by a chlorine.	2.07	1	carbazoles; monocarboxylic acid amide; organochlorine compound
alpha-synuclein alpha-Synuclein: A synuclein that is a major component of LEWY BODIES and plays a role in SYNUCLEINOPATHIES, neurodegeneration and neuroprotection.	2.11	1
tenovin-6 tenovin-6 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(dimethylamino)pentanoic acid with the aromatic amino group of N-[(4-aminophenyl)carbamothioyl]-4-tert-butylbenzamide.	3.31	1	monocarboxylic acid amide; tertiary amino compound; thioureas	antineoplastic agent; p53 activator; Sir2 inhibitor
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.1	1	benzenes; hydroxycoumarin; methyl ketone
amyloid beta-peptides amyloid beta-protein (1-40): although acutely neurotoxic in both rat & monkey cerebral cortex, neuronal degeneration in primates resembles more closely to that found in Alzheimer's disease; amino acid sequence has been determined	2.13	1
n-(3-((2-hydroxynaphthalen-1-ylmethylene)amino)phenyl)-2-phenylpropionamide [no description available]	2.49	2

Condition	Relationship Strength	Studies
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.39	6
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Cognitive Decline [description not available]	2.25	1
Academic Disorder, Developmental [description not available]	2.25	1
Age-Related Memory Disorders [description not available]	2.25	1
Learning Disabilities Conditions characterized by a significant discrepancy between an individual's perceived level of intellect and their ability to acquire new language and other cognitive skills. These may result from organic or psychological conditions. Relatively common subtypes include DYSLEXIA, DYSCALCULIA, and DYSGRAPHIA.	2.25	1
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	2.25	1
Cognitive Dysfunction Diminished or impaired mental and/or intellectual function.	2.25	1
Encephalopathy, Traumatic [description not available]	2.31	1
Brain Injuries, Traumatic A form of acquired brain injury which occurs when a sudden trauma causes damage to the brain.	2.31	1
Idiopathic Parkinson Disease [description not available]	2.53	2
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	2.53	2
Apoplexy [description not available]	2.17	1
Cerebral Ischemia [description not available]	2.54	2
Injury, Ischemia-Reperfusion [description not available]	2.17	1
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	2.54	2
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	2.17	1
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	2.17	1
Cranial Nerve XII Injury [description not available]	2.17	1
ALS - Amyotrophic Lateral Sclerosis [description not available]	2.11	1
Amyotrophic Lateral Sclerosis A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)	2.11	1
Autosomal Dominant Juvenile Parkinson Disease [description not available]	2.52	2
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.52	2
Parkinsonian Disorders A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.	2.52	2
Acute Confusional Senile Dementia [description not available]	2.13	1
Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.	2.13	1
Glial Cell Tumors [description not available]	2.13	1
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.13	1
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.13	1

3-(1-azepanylsulfonyl)-n-(3-bromphenyl)benzamide

Description

Cross-References

Synonyms (44)

Research Excerpts

Bioavailability

Dosage Studied

Protein Targets (13)

Potency Measurements

Inhibition Measurements

Biological Processes (199)

Molecular Functions (59)

Ceullar Components (55)

Bioassays (69)

Research

Studies (25)

Market Indicators

Research Demand Index: 11.30

Study Types

3-(1-azepanylsulfonyl)-n-(3-bromphenyl)benzamide

Description

Cross-References

Synonyms (44)

Research Excerpts

Bioavailability

Dosage Studied

Protein Targets (13)

Potency Measurements

Inhibition Measurements

Biological Processes (199)

Molecular Functions (59)

Ceullar Components (55)

Bioassays (69)

Research

Studies (25)

Market Indicators

Research Demand Index: 11.30

Study Types

Related Drugs (27)

Related Conditions (30)